Semaglutide vs. Tirzepatide
100% Online — No Office Visit Required
Semaglutide and tirzepatide are both highly effective GLP-1 medications for weight loss — but they work differently and show different results in clinical trials.
Tirzepatide (dual GLP-1/GIP agonist) has shown greater average weight loss in trials compared to semaglutide (single GLP-1 agonist). However, individual response varies, and semaglutide may have a longer safety track record and potentially lower cost.
Side-by-Side Comparison
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 agonist | Dual GLP-1/GIP agonist |
| Brand names | Ozempic, Wegovy | Mounjaro, Zepbound |
| Average weight loss (trials) | ~15% of body weight | ~20–22% of body weight |
| Dosing | Weekly injection | Weekly injection |
| Track record | Longer (since 2021 for obesity) | Newer (2023 for obesity) |
Who Each Option May Fit
Who May Prefer Semaglutide
Patients who want a medication with a longer safety track record, or those who have responded well to semaglutide previously.
Who May Prefer Tirzepatide
Patients looking for the most effective option available, particularly those who haven't reached their goals with semaglutide or need more significant weight loss.
Common Questions
Can I switch from semaglutide to tirzepatide?
Yes, some patients switch medications. Your provider will guide you through the transition protocol if a switch is appropriate for your situation.
Ready to Get Started?
Complete a brief online intake. A licensed provider will review your information and determine if treatment is appropriate for you.
Medical Disclaimer: The information on this page is provided for educational purposes only and does not constitute medical advice. OakMD is a telemedicine platform. All treatments are prescription-based, subject to provider review, and may not be appropriate for all individuals. A licensed provider will evaluate your medical history and determine eligibility. Consult a qualified healthcare professional before starting any new treatment.